Search
Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10296ApprovedInvestigationalStreptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADETSynonyms: Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine, Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigenAP5280
go.drugbank.com/drugs/DB05112ExperimentalAP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Chloramphenicol
go.drugbank.com/drugs/DB00446ApprovedInvestigationalVet approvedWithdrawnAn antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. … It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic.
Synonyms: D-(−)-2,2-dichloro-N-(β-hydroxy-α-(hydroxymethyl)-p-nitrophenylethyl)acetamideMixtures: SPERSADEX COMP. ® SOLUCIÓN OFTÁLMICAPyrantel
go.drugbank.com/drugs/DB11156ApprovedVet approvedPyrantel is mainly available in formulations for dogs and cats as the embonate salt, containing a 34.7% pyrantel base [L1900]. … Pyrantel has shown to be effective after a single dose [L1905]. In humans, it is administered as pyrantel pamoate [A32282],[A32283],[L1893],[L1898].
Products: PIREL® SUSPENSION AL 5%, Pin-XBromhexine
go.drugbank.com/drugs/DB09019ApprovedInvestigationalBromhexine is mucolytic agent used for a variety of respiratory conditions associated with increased mucus secretion. … It was introduced into the market in 1963, and is widely available as an over-the-counter drug in many countries.
Mixtures: GLICERTOX N FSynonyms: N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine, 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamineDonepezil
go.drugbank.com/drugs/DB00843ApprovedInvestigationalIn 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. … [A182411] Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage
Products: DONEPEZIL WIN MEDICA, DONEPEZIL AL 5 MGDifelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes … [A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions.
Zenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigationalZenocutuzumab is a low-fucose humanized full-length immunoglobulin G1 (IgG1) bispecific HER2- and HER3-directed bispecific antibody. … [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma.
Erdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalErdosteine is a drug that causes a breakdown of mucus, also known as a _mucolytic_ agent. … It is a _thiol_ derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis.
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawna 68% reduction in the risk of death were observed. … This approval is based on positive results obtained from a multi-site, single-arm, externally controlled study of children with high-risk neuroblastoma, where a 52% reduction in the risk of relapse and